Antibody

1,010개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,010 programs
AntibodyLimited DatastaleEpizyme, Inc.Phase 2

Tafasitamab (Tafasitamab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#RelapsedHematologicMalignancy+3
Trials 48Status Discontinued
AntibodyLimited DatastaleChia Tai Tianqing Pharmaceutica…Phase 2

Penpulimab (Penpulimab)

Advanced Malignant Neoplasm · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#AdvancedMalignantNeoplasm+2
Trials 47Status Active
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

NAI (Nogapendekin Alfa-Inbakicept, Nogapendekin Alfa-Inbakicept (NAI))

Acute Respiratory Distress Syndrome; Severe Community-Acquired Pneum · Acute Respiratory Distress Syndrome

#AcuteRespiratoryDistressSyndrome#Antibody#Phase2#monoclonal-antibody#SevereCommunity-AcquiredPneum+2
Trials 46Status Discontinued
AntibodyLimited DatastaleGruppo Oncologico del Nord-OvestPhase 2

Balstilimab (Balstilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ResectableColorectalCarcinoma+1
Trials 45Status Recruiting
AntibodyLimited DatastaleIndiana Hemophilia &Thrombosis …Approved

Emicizumab (Emicizumab)

Haemophilic Pseudotumour · Factor VIII Deficiency, Congenital

#FactorVIIIDeficiencyCongenital#Antibody#Approved#monoclonal-antibody#HaemophilicPseudotumour+2
Trials 45Status Discontinued
AntibodyLimited DatastaleNew Approaches to Neuroblastoma…Phase 1

Dinutuximab (Dinutuximab)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#Antibody#Phase1#monoclonal-antibody#NKcellsbyacombinatorialimmunothe+1
Trials 44Status Recruiting
AntibodyLimited DatastaleJack Khouri, MDPhase 2

Siltuximab (Siltuximab)

Multiple Myeloma; Cytokine Release Syndrome · Myelofibrosis

#Myelofibrosis#Antibody#Phase2#monoclonal-antibody#MultipleMyeloma+3
Trials 43Status Recruiting
AntibodyCurated CorestaleLEO PharmaApproved

Tralokinumab (Tralokinumab)

Psoriasis; Atopic Dermatitis · Atopic Dermatitis

#AtopicDermatitis#Antibody#Approved#BioJungboMoa-pick#monoclonal-antibody+3
Trials 43Status Recruiting
AntibodyLimited DatastaleHuiKai LiPhase 2

Pucotenlimab (Pucotenlimab)

Biliary Tract Cancer (BTC); EGFR-positive Advanced Biliary Tract Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#Antibody#Phase2#monoclonal-antibody#BiliaryTractCancerBTC+2
Trials 42Status Recruiting
AntibodyLimited DatastaleAlmirall, S.A.Approved

Tildrakizumab (Tildrakizumab)

Psoriasis; Atopic Dermatitis · Psoriasis

#Psoriasis#Antibody#Approved#monoclonal-antibody#AtopicDermatitis+1
Trials 41Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Ocrelizumab, Rituximab, Ofatumumab (Anti-CD20 therapies, Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab))

Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy · CD20

#CD20#Antibody#Phase3#monoclonal-antibody#Relapsing-RemittingMultipleScler+3
Trials 40Status Recruiting
AntibodyCurated CorestaleJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 40Status Discontinued
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#monoclonal-antibody#OvarianCancer+3
Trials 39Status Recruiting
AntibodyLimited DatastaleSanofiPhase 3

Isatuximab SAR650984 (Isatuximab SAR650984)

Immune System Disorder · Plasma Cell Myeloma

#PlasmaCellMyeloma#Antibody#Phase3#monoclonal-antibody#ImmuneSystemDisorder+2
Trials 39Status Active
AntibodyLimited DatastaleGruppo Oncologico del Nord-OvestPhase 2

Botensilimab (Botensilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ResectableColorectalCarcinoma+1
Trials 38Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Hu5F9-G4 (Magrolimab, Magrolimab (Hu5F9-G4))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 35Status Active
AntibodyLimited DatastaleJazz PharmaceuticalsPhase 2

Zanidatamab (ZW25, ZW25 (Zanidatamab))

HER2+/HR+ Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2++3
Trials 33Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#NonSmallCellLungCancer+1
Trials 32Status Recruiting
AntibodyLimited DatastaleAnaveon AGPhase 2

KEYTRUDA® (ANV600 + pembrolizumab, ANV600 + pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#bispecificantibody-cytokinefusio+1
Trials 31Status Recruiting
AntibodyLimited DatastaleETOP IBCSG Partners FoundationPhase 3

durvalumab (Imfinzi, Adjuvant durvalumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ETOP
Trials 31Status Recruiting

7 / 51 pages

← PreviousNext →